RecruitingPHASE2INTERVENTIONAL

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

This study is designed for cancer patients who are currently receiving treatment with a drug called adagrasib in other research studies. If their current treatment with adagrasib (either by itself or combined with other cancer medications like pembrolizumab or cetuximab) is helping their non-small cell lung cancer, colorectal cancer, or other advanced solid tumours, they may be able to continue receiving it in this new study. It's an 'open-label' study, meaning both patients and doctors will know what treatment is being given. The main goal is to understand the long-term effects and benefits of adagrasib for patients with these types of cancer. This study helps ensure that individuals benefiting from a treatment can continue to access it.

At a glance

Status

Recruiting

Phase

PHASE2

Sponsor

Mirati Therapeutics Inc.

Enrolment target

170

Start

06 May 2026

Estimated completion

16 Feb 2028

Solid Tumors

What is this study about?

This research study is for people who have been diagnosed with certain types of cancer and are already participating in another study that uses a medicine called adagrasib. Adagrasib is a drug that helps fight various 'solid tumours' – these are cancers that form solid lumps, like lung or bowel cancer.

Sometimes, when a new medicine is being tested, if it's found to be helpful for patients, there's a way for those patients to continue receiving it. This study is exactly that – a 'continuation study'. It allows patients who are already seeing a benefit from adagrasib in previous research to keep getting the treatment. This is important because it means if a medicine is working well for you, you won't necessarily have to stop taking it just because the initial study ended.

The study also aims to gather more information about adagrasib's long-term effects. Doctors want to understand better how it works over a longer period, both when used on its own and when combined with other cancer treatments you might have received in the original study. This helps them learn more about the best ways to use adagrasib for patients with cancers like non-small cell lung cancer and colorectal cancer.

Key takeaways

This study is for patients already taking part in an adagrasib cancer trial.
It allows continued access to adagrasib if it's helping your cancer.
The study aims to understand the long-term effects of adagrasib for solid tumours.
It involves regular check-ups and monitoring of your health.
You can discuss with your doctor if this continuation study is right for you.

Who may be eligible?

To join this study, you must already be taking part in another research study that uses the drug adagrasib. Your doctor must also agree that the treatment is still benefiting you. If you were born female and are still able to have children, you must provide proof that you are not pregnant and agree to use effective birth control methods during the study if you are sexually active.

You cannot join this study if you are no longer eligible for treatment in your original study. Also, if you’ve already finished the adagrasib treatment, or if your cancer got worse, or if you had to stop treatment in the original study because of bad side effects, then this study is not for you. Finally, if your doctor doesn't think the treatment is helping you anymore, you won't be able to join this continuation study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I currently in another research study receiving adagrasib treatment?
Does my study doctor believe I am still benefiting from the adagrasib treatment?
Did I *not* have to stop my previous treatment due to side effects or worsening cancer?
If I was born female, have I confirmed I’m not pregnant and will use birth control if sexually active?

Answer every question to see your result.

What does participation involve?

If you join this study, you will continue to receive the adagrasib treatment, potentially along with other cancer medicines, just as you did in your previous study. The study team will regularly check how you're feeling and how the treatment is working. This will involve regular visits to the clinic, which may include physical examinations, blood tests, and scans to monitor your cancer. The exact schedule will depend on what was established in your original study. You'll continue with these assessments to ensure the treatment is still safe and effective for you. The total duration of your participation will depend on how long the treatment continues to help you, or until you experience side effects that require you to stop.

Potential risks and benefits

One potential benefit of joining this study is that you can continue receiving a cancer treatment that has already shown signs of helping you. This means you might avoid the interruption of a successful treatment. As with all medications, adagrasib and any other treatments you receive have potential side effects, which you would have already experienced or been told about in your initial study. These could range from mild to serious, and the study team will monitor you closely for them. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (100)

Local Institution - 0005
Verified postcode
Phoenix, United States· Withdrawn
Southern California Permanente Medical Group
Verified postcode
Bellflower, United States· Recruiting
Local Institution - 0082
Verified postcode
Long Beach, United States· Not yet recruiting
Local Institution - 0003
Verified postcode
Newark, United States· Withdrawn
Florida Cancer Specialists - North
Verified postcode
St. Petersburg, United States· Recruiting
Local Institution - 0112
Verified postcode
Wichita, United States· Not yet recruiting
Local Institution - 0092
Verified postcode
Boston, United States· Not yet recruiting
Local Institution - 0080
Verified postcode
Boston, United States· Not yet recruiting
Mayo Clinic in Rochester, Minnesota
Verified postcode
Rochester, United States· Recruiting
Local Institution - 0073
Verified postcode
Saint Paul, United States· Not yet recruiting
Local Institution - 0036
Verified postcode
Omaha, United States· Not yet recruiting
Oncology Associates Of Oregon, Pc
Verified postcode
Eugene, United States· Recruiting

Common questions

What is adagrasib?

Adagrasib is a medicine being tested to treat certain types of cancer, often solid tumours like lung or bowel cancer.

Who is this study for?

This study is for people who are already in another research study and taking adagrasib, and who are still benefiting from it.

What is a 'continuation study'?

It means if a medicine in a previous study is helping you, this study allows you to keep receiving that treatment for longer.

Will I know what treatment I'm getting?

Yes, this is an 'open-label' study, so both you and your doctors will know which treatments you are receiving.

Can I stop participating if I want to?

Yes, you can choose to leave the study at any time, and it won't affect your regular medical care.

How to find out more

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

clinical.trials@bms.com 855-907-3286 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.